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he regulation of islet hormone secretion in vivo
is likely to involve a complex interplay between
circulating nutrients, hormones, and neurotrans-
mitters (1). A new study by Hauge-Evans et al.
(2) in this issue provides interesting new insights into the
contribution of an intraislet paracrine role for somatosta-
tin in the control of insulin, and more especially glucagon,
release.
Glucagon is the principal counterregulatory hormone
that opposes the anabolic effects of insulin, notably on the
liver (3), and a relative excess of glucagon is a hallmark of
all forms of diabetes. However, failure to secrete adequate
quantities of glucagon in response to insulin-induced hy-
poglycemia characterizes longstanding type 1 diabetes (4)
and is an important contributor to mortality in this dis-
ease, accounting for 2–4% of all deaths (5).
Glucagon is stored alongside insulin in the islet, albeit in
a discrete cellular compartment, the pancreatic -cell. Just
as the metabolic actions of glucagon oppose those of
insulin, the regulators of insulin’s release (1) tend to exert
opposing effects on glucagon secretion (6). Thus, elevated
concentrations of glucose suppress glucagon release,
while catecholamines stimulate the secretion of this hor-
mone. Acting independently of these mechanisms, neuro-
nal inputs into the islet exert a further important level of
control over glucagon release (7).
Despite being a subject under investigation for more
than 35 years (6), just how the effects of glucose are
achieved at the level of individual -cells is still disputed
and has become an area of vigorous research in recent
times (Figure 1). As yet, however, a consensus has not
been reached. Several laboratories (e.g., 8), including the
author’s (9), have concluded that glucose acts directly on
isolated mouse -cells to suppress oscillations in intracel-
lular free Ca
2 concentration in the absence of paracrine
inﬂuences from -cells (the latter parameter is usually
taken in these excitable cells as an adequate surrogate for
electrical and secretory activity). The Ca
2 changes were
associated with increases in intracellular free ATP concen-
tration (9), which might be “decoded” via 1) the partial
closure of ATP-sensitive K
 channels (KATP), resulting in
the inactivation of N-type Ca
2 and voltage-gated Na

channels, suppression of electrical activity, and Ca
2
inﬂux through L-type Ca
2 channels (1,10); 2) through the
activation of Ca
2 uptake by the endoplasmic reticulum,
the consequent inactivation of a store-operated current
that results in plasma membrane hyperpolarization, and
decreased Ca
2 inﬂux through voltage-gated Ca
2 chan-
nels (11); and 3) through changes in the activity of
nutrient-regulated protein kinases including AMP kinase
(12).
An alternative model has become known as the “in-
traislet” or “switch off” hypothesis. Informed by the strik-
ingly “anti-parallel” regulation of insulin and glucagon
secretion, this posits that factors released from the -cell
as glucose levels rise, including insulin itself (13) and
cosecreted species such as -aminobutyric acid (GABA)
(14–16) and Zn
2 ions (1,17,18), suppress the release of
glucagon in a paracrine manner. This idea is supported
by the fact that the intraislet circulation appears to be
from -t o-cell (19) and by the clinical observation that
treatment of type 1 diabetic subjects with insulin usually
lowers glucagon levels. Finally, puriﬁed rat -cells have
been reported to respond to elevated glucose concentra-
tions with enhanced glucagon secretion (20) (though the
impact of the ﬂuorescence-activated cell sorting on the
functional integrity of these preparations is uncertain).
However, the “switch off” hypothesis has been challenged
(8,9) on the grounds that the concentrations of glucose
that almost fully inhibit glucagon release from isolated
rodent (8) and human islets (3–4 mmol/l) are signiﬁcantly
below those that elicit detectable depolarization of the
-cell or the release of insulin and costored regulators
(5.5–6 mmol/l). The existence of highly local “microdo-
mains” of the regulators in the interstitial space between
local - and -cells must therefore be invoked to sustain
this hypothesis.
The release of an inhibitor of glucagon release over a
range of glucose concentrations that more closely match
that which regulates glucagon secretion would potentially
provide a more attractive means of controlling -cell
activity. Enter somatostatin. Stored in pancreatic -cells,
release of somatostatin is controlled similarly to that of
insulin, but with the crucial difference that the secretion of
somatostatin is already substantially stimulated by glucose
concentrations as low as 3 mmol/l (half-maximal effects
are observed at 6 mmol/l) (8). Existing evidence that
somatostatin may be involved in controlling the release of
glucagon in response to changes in glucose concentration
is mixed. Supporting this view, exogenously added soma-
tostatin potently inhibits glucagon release from the pan-
creas (21), while anti-somatostatin antibodies activate
glucagon release from isolated islets (22). However, stud-
ies with the isolated perfused pancreas have argued both
for (23) and against (24) a role for locally acting soma-
tostatin on glucagon release. Finally, the selective soma-
tostatin receptor type 2 (SSTR2) antagonist DC-41-33 only
weakly enhanced glucagon secretion from the perfused rat
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strongly potentiating the response to arginine (25).
The important new study by Hauge-Evans et al. (2)
provides a key step forward by exploring the effects on
glucagon and insulin release of the deletion, through
homologous recombination, of the somatostatin gene in
mice. SST
/ mice have previously been described to
show a relatively modest phenotype including changes in
the release of pituitary hormones (26). The new study
shows ﬁrst that arginine-induced release of insulin and
glucagon is markedly stimulated in vivo when somatosta-
tin is absent. Moreover, in islets isolated from SST
/
mice, the normal inhibition of glucagon release by glucose
was eliminated, while the stimulation of insulin release by
the sugar was enhanced. On the other hand, the rapid
inhibition of insulin secretion upon glucose lowering was
unaltered in SST
/ mice, questioning a role for soma-
tostatin in this process.
These studies thus further emphasize the contribution
of somatostatin as a tonic inhibitor of glucagon release
during stimulation by low glucose concentrations or after
challenge with arginine. The work also provides a power-
ful adjunct to earlier studies using pharmacological ap-
proaches, as well as those using SSTR2
/ mice (27).
However, there remain uncertainties: SST was deleted
unconditionally throughout the body in the present stud-
ies, providing the possibility for an indirect developmental
effect on the regulation of glucagon secretion by other
mechanisms (Figure 1); microarray proﬁling of islets from
SST
/ mice may be informative to explore whether other
changes occur in the expression of key genes in either -
or -cells to limit the ability of glucose to control glucagon
release normally.
The studies raise several important new questions: 1)I s
the whole panoply of putative regulatory mechanisms
(Figure 1) really important in vivo, and if so, under what
conditions? 2) Do they same mechanisms play a role(s) in
humans as well as rodents? 3) Given the effects of
somatostatin deletion to enhance insulin and glucagon
secretion, respectively, might somatostatin receptor antag-
onists prove useful to treat hyperglycemia in type 2
diabetes and hypoglycemia in type 1 diabetes? Imaginative
new approaches seem likely to be needed to address these
points: studies of SST
/ mice under hypoglycemic clamp
may be particularly informative to conﬁrm or refute the
importance of a decrease in somatostatin release to the
activation of glucagon secretion in vivo. Additionally, a
more detailed molecular exploration of other proposed
mechanisms, for example, by -cell–speciﬁc deletion of
insulin or GABA receptors, or the islet-speciﬁc Zn
2
transporter, ZnT8 (28), in mice is also needed.
Although understanding of the regulation of glucagon
release still remains incomplete, the new insights about
the importance of somatostatin provided by Hauge-Evans
et al. (2) may allow the more rational design and use of
drugs to modulate glucagon (and insulin) release in all
forms of diabetes.
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FIG. 1. Multiple mechanisms of control of glucagon secretion. For details, see the text. ER, endoplasmic reticulum; Nav,C a v, voltage-gated Na

and Ca
2 channels, respectively; NTs, neurotransmitters.
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